Who
Geno J. Germano
Director
Company insider
Files Form 4 as: Director, Eloxx Pharmaceuticals; Director, Precision BioSciences; Director, Entera Bio; Director, Harmony Biosciences Holdings; Director, Sage Therapeutics; Director, Medicines Co /de; Director, Bioverativ; President, Precigen.
In numbers
- Trades disclosed
- 158
- Buys
- 7
- Sells
- 3
- Bought
- $322K
- Sold
- $2.2M
- Companies
- 11
- Companies where not an officer
- 8
- First trade
- 29 Feb 2008
- Last trade
- 19 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 21 Oct 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,587 at $0.00 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DTIL Precision BioSciencesBiotechnology | SEC FORM 4 Bought | $16K2,609 at $6.28 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DTIL Precision BioSciencesBiotechnology | SEC FORM 4 Bought | $16K2,609 at $6.28 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —25,014 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —43,014 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —43,014 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —25,014 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DTIL Precision BioSciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,979 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DTIL Precision BioSciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,979 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | DTIL Precision BioSciencesBiotechnology | SEC FORM 4 Code M | —21,000 | filing |
| 20 May 2026filed 22 May 2026 | DTIL Precision BioSciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | DTIL Precision BioSciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | DTIL Precision BioSciencesBiotechnology | SEC FORM 4 Code M | —21,000 | filing |
| 14 May 2026filed 18 May 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —21,231 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —21,231 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $26K20,000 at $1.30 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $26K20,000 at $1.30 | filing |
| 10 Feb 2026filed 11 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $30K20,000 at $1.49 | filing |
News
Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Price Target of $32.25DTIL · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Geno J. Germano; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.